Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’

被引：0
|
作者：
Andrew Rowland
Mafalda M Dias
Michael D Wiese
Ganessan Kichenadasse
Ross A McKinnon
Christos S Karapetis
Michael J Sorich
机构：
[1] School of Medicine,Department of Clinical Pharmacology
[2] Flinders University,undefined
[3] Flinders Centre for Innovation in Cancer,undefined
[4] School of Medicine,undefined
[5] Flinders University,undefined
[6] School of Pharmacy and Medical Sciences,undefined
[7] University of South Australia,undefined
来源：
British Journal of Cancer | 2015年 / 113卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1635 / 1635
相关论文
共 50 条
  • [41] A multicenter randomized clinical trial evaluating the negative hyperselection of patients with RAS/BRAF wild-type metastatic colorectal cancer who are eligible for anti-EGFR therapy
    Pokataev, I.
    Tryakin, A.
    Fedyanin, M.
    Antonova, T.
    Semenova, A.
    Lebedeva, A.
    Kuznetsova, O. A.
    Veselovsky, E.
    Ivanov, M.
    Mileyko, V.
    Byakhov, M.
    Biakhova, M.
    Galkin, V.
    ANNALS OF ONCOLOGY, 2024, 35 : S481 - S481
  • [42] Triplet chemotherapy combined with anti-EGFR treatment in RAS wild-type colon cancer: A network meta-analysis
    Di Nardo, Paola
    Giudici, Fabiola
    Basile, Debora
    De Scordilli, Marco
    Torresan, Sara
    Bortolot, Martina
    Rota, Simone
    Foltran, Luisa
    Guardascione, Michela
    Fumagalli, Arianna
    Noto, Claudia
    Guglielmi, Alessandra
    Ongaro, Elena
    Puglisi, Fabio
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase II study
    Yang, Lin
    Zhang, Wen
    Fan, Nanfeng
    Cao, Peiguo
    Cheng, Ying
    Zhu, Lingjun
    Luo, Suxia
    Zong, Hong
    Bai, Yuxian
    Zhou, Jianfeng
    Deng, Yanhong
    Ba, Yi
    Liu, Tianshu
    Aili, Mayinuer
    Yin, Xianli
    Gu, Kangsheng
    Dai, Guanghai
    Ying, Jieer
    Shi, Jianhua
    Gao, Yajie
    Li, Wei
    Yu, Guohua
    Xie, Liangzhi
    Gai, Wenlin
    Wang, Yan
    Meng, Peng
    Shi, Yuankai
    EBIOMEDICINE, 2024, 100
  • [44] PREDICTIVE MOLECULAR BIOMARKERS IN COLORECTAL CANCER: IS KRAS AND BRAF WILD TYPE STATUS REQUIRED FOR ANTI-EGFR THERAPY?
    Marchoudi, N.
    Joutei, H. Amrani Hassani
    Jouali, F.
    Fekkak, J.
    Rhaissi, H.
    ANTICANCER RESEARCH, 2014, 34 (10) : 6048 - 6048
  • [45] PERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification
    Tabernero, J.
    Bekaii-Saab, T.
    Aguilera, M. Safont
    Cubillo, A.
    Garcia-Carbonero, R.
    Limon, L.
    Rodriguez-Salas, N.
    Tournigand, C.
    Borg, C.
    Raghav, K.
    Finley, G.
    Strickler, J.
    Beier, F.
    Salim, S.
    Esser, R.
    Liu, E.
    Adrian, S.
    Lopez-Lopez, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S136 - S137
  • [46] EGFR Protein Expression of KRAS Wild-Type Colorectal Cancer: Predictive Value of the Sidedness for Efficacy of Anti-EGFR Therapy
    Uhlyarik, A.
    Piurko, V
    Vizkeleti, L.
    Papai, Zs
    Raso, E.
    Lahm, E.
    Kiss, E.
    Sikter, M.
    Vachaja, J.
    Kenessey, I
    Timar, Jozsef
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (03) : 1429 - 1434
  • [47] Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer-PARADIGM Shift
    Robinson, Hannah R.
    Lieu, Christopher H.
    JAMA ONCOLOGY, 2023, 9 (06) : 767 - 769
  • [48] PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Mao, C.
    Yang, Z. Y.
    Hu, X. F.
    Chen, Q.
    Tang, J. L.
    ANNALS OF ONCOLOGY, 2012, 23 (06) : 1518 - +
  • [49] EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer
    Algars, Annika
    Sundstrom, Jari
    Lintunen, Minnamaija
    Jokilehto, Terhi
    Kytola, Soili
    Kaare, Milja
    Vainionpaa, Reetta
    Orpana, Arto
    Osterlund, Pia
    Ristimaki, Ari
    Carpen, Olli
    Ristamaki, Raija
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (04) : 922 - 929
  • [50] Identifying prognostic subgroups for outcomes in wild-type RAS metastatic colorectal cancer (mCRC) treated with anti-EGFR drugs
    Vladimirova, L.
    Kit, O.
    Abramova, N.
    Storozhakova, A.
    Popova, I.
    Tikhanovskaya, N.
    Ezhova, M.
    ANNALS OF ONCOLOGY, 2017, 28
12345